Geode Capital Management LLC Sells 2,365 Shares of MediWound Ltd. (NASDAQ:MDWD)

Geode Capital Management LLC lessened its stake in shares of MediWound Ltd. (NASDAQ:MDWD) by 2.4% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 95,302 shares of the biopharmaceutical company’s stock after selling 2,365 shares during the period. Geode Capital Management LLC owned 0.88% of MediWound worth $1,721,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in the company. MetLife Investment Management LLC bought a new position in MediWound during the third quarter valued at approximately $89,000. Rhumbline Advisers bought a new position in shares of MediWound during the 2nd quarter valued at approximately $131,000. Barclays PLC grew its holdings in shares of MediWound by 311.3% in the third quarter. Barclays PLC now owns 11,163 shares of the biopharmaceutical company’s stock valued at $202,000 after purchasing an additional 8,449 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in MediWound in the third quarter worth $212,000. Finally, Bank of New York Mellon Corp bought a new stake in MediWound in the second quarter worth $342,000. Hedge funds and other institutional investors own 46.83% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright lowered their price objective on shares of MediWound from $28.00 to $25.00 and set a “buy” rating for the company in a research report on Wednesday, November 27th.

MediWound Price Performance

Shares of NASDAQ MDWD opened at $16.01 on Thursday. The stock has a market capitalization of $172.68 million, a P/E ratio of -5.52 and a beta of 0.80. MediWound Ltd. has a 1-year low of $11.04 and a 1-year high of $24.00. The business’s 50 day moving average is $17.35 and its two-hundred day moving average is $17.63.

MediWound (NASDAQ:MDWD) last released its earnings results on Tuesday, November 26th. The biopharmaceutical company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.50). MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. During the same period in the prior year, the company posted ($0.24) EPS. As a group, equities research analysts anticipate that MediWound Ltd. will post -2.6 earnings per share for the current fiscal year.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.